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Abstract
Background: Experience using post-transplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD)
prophylaxis in allogeneic stem cell transplantation (HSCT) from matched sibling donors (MSD) or unrelated donors
(UD) is limited and with controversial results. The study aim was to evaluate PT-Cy as GVHD prophylaxis post-HSCT
from MSD and UD transplants. We analyzed 423 patients with acute leukemia who received PT-Cy alone or in
combination with other immunosuppressive (IS) drugs as GVHD prophylaxis. Seventy-eight patients received PT-Cy
alone (group 1); 204 received PT-Cy in combination with one IS drug—cyclosporine-A (CSA) or methotrexate (MTX)
or mycophenolate-mofetil (MMF) (group 2), while 141 patients received PT-Cy in combination with two IS
drugs—CSA +MTX or CSA + MMF (group 3). Transplants were performed from 2007 to 2015 and median follow-up
was 20 months.
Results: Probability of overall survival (OS) at 2 years was 50, 52.2, and 62.4%, for the three groups, respectively, p = 0.06.
In multivariate analysis, in comparison to PT-Cy alone, the addition of two IS drugs was associated with reduced risk of
extensive cGVHD (HR 0.25, p = 0.02). Use of bone marrow (BM) and anti-thymocyte globulin were independently associated
with reduced risk of extensive cGVHD. Prognostic factors for non-relapse mortality (NRM) were the addition of two IS drugs
to PT-Cy (HR 0.35, p = 0.04), diagnosis of AML, disease status at transplant, and patient CMV serology. Factors associated
with increased OS were the use of PT-Cy with two IS drugs (HR 0.49, p = 0.02), AML, and disease status at transplant.
Conclusion: For GVHD prophylaxis in MSD and UD HSCT, the addition of IS drugs to PT-Cy enhances its effect and reduces
the risk of severe cGVHD, reducing mortality and improving survival.
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Background
Graft-versus-host disease (GVHD) remains one of the
main life-threatening complications after allogeneic stem
cell transplantation (HSCT) [1, 2]. The standard GVHD
prophylaxis strategy is mostly based on the use of
calcineurin inhibitors alone or in combination with
other immunosuppressive (IS) drugs [3, 4]. This results
in an incidence of 25–40% of acute GVHD and 40–60%
of chronic GVHD after HSCT from HLA identical
sibling (MSD) or unrelated donor (UD). The incidence
of GVHD also depends on the conditioning regimen as
well as patients and disease-related factors [5].
With the increased use of HSCT from unmanipulated
haploidentical donor, adapted GVHD prophylaxis has
been proposed [6, 7]. Among those, Luznik et al. [7]
pioneered the use of high-dose post-transplant cyclo-
phosphamide (PT-Cy) in combination with other IS
drugs reporting a low incidence of acute (a) and chronic
(c) GVHD and low transplant-related mortality.
The feasibility of PT-Cy in the haploidentical setting
has prompted its use as sole GVHD prophylaxis in re-
cipients of HSCT from MSD or UD [8, 9]. Luznik et al.
[8] reported 43 and 10% of grades II–IV and III–IV
aGVHD, respectively, and 10% of cGVHD in 117 pa-
tients receiving bone marrow (BM) transplantation from
MSD with myeloablative regimen. Similar results were
observed in a multicenter study [9].
However, the attempts to administer PT-Cy alone, in a
phase 2 trial on adult patients with hematologic malig-
nancies undergoing HSCT with peripheral blood stem
cell (PBSC) grafts from either HLA identical sibling or
unrelated donors, was associated with severe aGVHD
and related deaths [10].
Mielcarek et al. [11] reported the use of PT-Cy
followed by cyclosporine A (CSA), started on day + 5
post stem cell infusion, resulting in low incidence of se-
vere aGVHD, but grade II–IV aGVHD and extensive
cGVHD reached 77 and 30%, respectively.
More recently, the use of PT-Cy combined with
other IS such as tacrolimus or mycophenolate mofetil
(MMF) was shown to reduce the incidence of acute
and chronic GVHD to 19 and 16%, respectively, in
PBSC recipients [12].
We aimed to analyze PT-Cy alone or in combination
with other IS as GVHD prophylaxis in a large cohort of pa-
tients transplanted for acute myeloid leukemia (AML) or
acute lymphoblastic leukemia (ALL) and reported to the
European Society for Blood and Marrow Transplantation
(EBMT) Registry.
Methods
Study design
This is a retrospective registry-based analysis on behalf
of the Acute Leukemia Working Party (ALWP) of the
EBMT. The EBMT is a voluntary working group of more
than 550 transplant centers that are required to report
all consecutive stem cell transplantations and follow-up
once a year. Audits are routinely performed to deter-
mine the accuracy of the data.
Adults (age > 18 years) with AML or ALL in complete
remission (CR1 or CR2) or in advanced disease at trans-
plant, reported to Promise-EBMT, who underwent a
HSCT with MSD or 10/10 HLA matched UD using PT-
Cy as first allogeneic HSCT between 2007 and 2015
were analyzed.
This study was approved by the ALWP of the EBMT
institutional review board and conducted in accordance
with the Declaration of Helsinki and Good Clinical Prac-
tice guidelines. All patients or legal guardians provided
written informed consent authorizing the use of clinical
information for research purposes.
A total of 423 patients were reported from 150 trans-
plant centers, including 78 patients receiving PT-Cy
alone (group 1) and 204 patients receiving PT-Cy in
combination with one IS, mainly CSA or metothrexate
(MTX) or MMF (group 2), while 141 patients received
PT-Cy in combination with two IS drugs—CSA +MTX
or CSA +MMF (group 3).
End points and definitions
The primary end point was leukemia-free survival (LFS).
Secondary end points were neutrophil engraftment,
aGVHD and cGVHD, relapse incidence (RI), non-
relapse mortality (NRM), GVHD-free relapse-free sur-
vival (GRFS), and overall survival (OS).
Neutrophil engraftment was defined as the first of 3
consecutive days with a neutrophil count of at least
0.5 × 109/L. Acute GVHD was graded according to the
modified Seattle Glucksberg criteria [13] and cGVHD
according to the revised Seattle criteria [14]. Relapse was
defined as disease recurrence and appearance of blasts
in the peripheral blood or BM (> 5%) after CR. NRM
was defined as death from any cause other than relapse.
Refined GRFS [15] was defined as survival without the
following events: grade 3–4 acute GVHD, severe
cGVHD, disease relapse, or death from any cause after
transplantation. LFS was calculated until the date of first
relapse, death from any cause, or the last follow-up for
patients alive in CR.
Myeloablative conditioning (MAC) was defined as a
regimen containing either total body irradiation (TBI)
with a dose greater than 6 Gy, a total dose of oral
busulfan (Bu) greater than 8 mg/kg, or a total dose of
intravenous Bu greater than 6.4 mg/kg or melphalan
at doses > 140 mg/m2. In addition, regimens contain-
ing two alkylating agents were also considered as
MAC. All other regimens were defined as reduced in-
tensity conditioning (RIC).
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Statistical analysis
Quantitative variables are described with median and
range. Categorical variables are reported with counts
and percent.
LFS and OS and GRFS were estimated by the Kaplan–
Meier method. Cumulative incidence (CI) functions
were used to estimate neutrophil engraftment, NRM,
aGVHD, cGVHD, and RI. Competing risks were death
for RI, relapse for NRM, and relapse or death for
aGVHD and cGVHD. Univariate analyses were done
using the log-rank test for GRFS, OS, and LFS, and
Gray’s test for CI. For univariate analysis, comparisons
were done using chi-square tests for categorical and
Mann-Whitney tests for continuous variables. Multivari-
ate analyses were performed using the Cox proportional
hazard model.
There was no interaction between the different GVHD
prophylaxis strategy and donor type; therefore, they were
analyzed together.
Type of GVHD prophylaxis, diagnosis, disease status,
age at transplant, transplant year, donor relatedness,
stem cell source, cytomegalovirus (CMV) serostatus
(donor and recipient negative vs. other combination),
conditioning regimen, use of in vivo T cell depletion
(anti-thymocyte globulin, ATG), and center experience
were included in the final model. In order to test for
center effect, we introduced a random effect or frailty
for each center into the model [16].
The significance level was fixed at 0.05, and p values
were two-sided. Statistical analyses were performed with
the SPSS 22 (SPSS Inc./IBM, Armonk, NY, USA) and R
3.2.3 (R Development Core Team, Vienna, Austria) soft-
ware packages.
Results
Patient and transplant characteristics
Table 1 summarizes the main characteristics by the
GVHD prophylaxis strategies. Four hundred twenty-
three patients were included in this study; most patients
in both groups were transplanted for AML in CR1. The
median follow-up was 20 months (95% CI 17.6–22.6).
Patients in group 1 were younger (median age 37 years,
p < 0.001) and transplanted in more recent years (2014,
p < 0.001), received more frequently grafts from a MSD
(80%, p < 0.001) and from a CMV-positive donor (73%,
p = 0.008). In addition, group 1 received more often RIC
(56%, p < 0.001) and BM as source of stem cells (74%,
p < 0.001), with no ATG (100%, p < 0.001). Twenty-eight
centers used ATG in combination with PT-Cy used, cor-
responding to 143 patients. Dose of ATG was available
for 87 patients. Median dose for Thymoglobulin was
5 mg/kg (range 2.5–10 mg/kg). It was 50 mg/kg for
ATG-Fresenius (range 20-60 mg/kg).
Neutrophil engraftment and GVHD
Patients receiving PT-Cy alone had 90% (95%CI 80.4–95.5)
of neutrophil engraftment at 60 days, whereas it was 97%
(95%CI 93.1–98.7) for patients in group 2 and 96.6%
(95%CI 90.2–98.1) for group 3, p < 0.001. The median time
to engraftment was longer for patients receiving PT-Cy
alone (22 days), vs. 17.5 and 15 days for patients in groups
2 and 3, respectively.
CI of day 100 grade II–IV aGVHD and 1 year cGVHD
were 27.9 and 33%, respectively.
In adjusted multivariate analysis (Table 2), there was
no difference in the risk of grade II–IV aGVHD (group 1
vs. group 2 HR 0.63, 95%CI 0.28–1.3, p = 0.23; group 1
vs. group 3 HR 1.4, 95%CI 0.65–3.14, p = 0.38) and
grade III–IV aGVHD (group 1 vs. group 2 HR 0.52,
95%CI 0.17–1.5, p = 0.25; group 1 vs. group 3 HR 0.81,
95%CI 0.27–2.44, p = 0.71) according to the groups.
Diagnosis of ALL (HR 0.57, 95%CI 0.32–0.84, p < 0.001),
UD (HR 1.65, 95%CI 1.1–2.6, p = 0.02), RIC regimen (HR
1.72, 95%CI 1.1–2.7, p = 0.01), and donor CMV positive
(HR 1.77, 95%CI 1.1–2.8, p = 0.01) were independently
associated with increased risk of grade II–IV aGVHD.
The type of GVHD prophylaxis did not impact the CI
of cGVHD (31, 34, and 33% p = 0.92, respectively)
(Fig. 1a). Similarly, the intensity of the GVHD prophy-
laxis was not associated with cGVHD (group 1 vs. group
2 HR 0.60, 95%CI 0.26–1.36, p = 0.22; group 1 vs. group
3 HR 0.54, 95%CI 0.22–1.23, p = 0.13) in the multivari-
ate analysis (Table 2).
The use of BM (HR 0.41, 95%CI 0.28–0.48, p = 0.01)
and the absence of ATG (HR 0.59, 95%CI 0.36–0.94,
p = 0.03) were independently associated with a reduced
risk of cGVHD.
The incidence of extensive cGVHD was higher for
patients receiving PT-Cy alone (18%) or PT-Cy + 1 IS
(20%) vs. 8.5% for those having PT-Cy + 2 IS (Fig. 1b).
This was also confirmed in the multivariate analysis
(Table 2) where in comparison to PT-Cy the addition of
two IS was associated with reduced risk of extensive
cGVHD (group 1 vs. group 2, HR 0.56, 95%CI 0.20–1.5,
p = 0.27; group 1 vs. group 3, HR 0.25, 95%CI 0.07–0.84,
p = 0.02). The use of BM vs. PBSC grafts (HR 0.21,
95%CI 0.07–0.62, p < 0.001) and the absence of ATG
(HR 0.22, 95%CI 0.09–0.54, p < 0.001) were also inde-
pendently associated with reduced risk of extensive
cGVHD.
Relapse and NRM
At 2 years, the CI of relapse for the whole cohort was
33% with no difference according to groups (32 vs. 36
vs. 28%, p = 0.47) (Fig. 2a). CI of relapse was 33.9% for
AML and 32.1% for ALL, p = 0.04, and it was 27.4, 38.5,
and 47% for patients transplanted in CR1, CR2, and in
advanced disease status p < 0.01, respectively. According
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to donor type, CI of relapse was 37.5 and 28.5% for
MSD and UD, p = 0.21, respectively.
Overall, 2 years NRM was 18% with no difference for
the three groups (19 vs. 20 vs. 14%, p = 0.47) (Fig. 2b).
Overall, main causes of death were disease recurrence
(50%), infections (17%), and GVHD (15%).
In multivariate analysis (Table 2), the type of GVHD
prophylaxis was not associated with relapse, with ad-
vanced disease status accounting for an increased risk of
relapse (HR 2.42, 95%CI 1.60–3.66, p < 0.001).
As for NRM (Table 2), the addition of two IS to
the PT-Cy (group 1 vs. group 3) (HR 0.35, 95%CI
0.12–0.91, p = 0.04), the diagnosis of AML (HR 0.35,
95%CI 0.18–0.66, p = 0.001), advanced disease status
at transplant (HR 2.94, 95%CI 1.65–5.29, p < 0.001),
and patient CMV positive serology (HR 2.04, 95%CI
1.30–4.04, p = 0.04) were independently associated
with the risk of NRM.
OS, LFS, and GRFS
OS, LFS, and GRFS at 2 years were 55, 48, and 33%,
respectively. According to GVHD prophylaxis, OS was
50 vs. 52 vs. 62%, p = 0.06; LFS was 49% vs. 43% vs. 57%,
p = 0.08; and GRFS was 24% vs. 28% vs. 44%, p < 0.001,
for patients receiving PT-Cy alone or PT-Cy + 1 IS or
PT-Cy + 2 IS, respectively (Figs. 1c, 2c, d).
Table 1 Patient and disease characteristics
PTCy alone (n = 78) 1 associated drug (n = 204) 2 associated drugs (n = 141) p value
Median FU (median) 13.02 (10.13–15.9) 23.4 (20.15–26.7) 21.8 (15.42–28.12) < 0.001
AGE at Tx, median (range) (IQR) 37.1 (18.1–73.7)(27.5–49.8) 51.3 (18.7–72.9)(37.9–60.2) 43.9 (18.1–76)(31.5–54.1) < 0.001
Time diagnosis to Tx (months) 7.1 (2.1–81.8)(4.3–11.8) 5.3 (1.8–225.4)(3.7–10.8) 5.6 (0.4–186.9)(3.8–11.1) 0.137
Year of Tx, median (range) 2014 (2009–2015) 2013 (2008–2015) 2013 (2009–2015) < 0.001
AML 56 (72%) 172 (84%) 103 (73%) 0.014
ALL 22 (28%) 32 (16%) 38 (27%)
CR1 47 (60%) 135 (66%) 86 (61%) 0.366
CR2/3 8 (10%) 27 (13%) 24 (17%)
Active disease 23 (30%) 42 (21%) 31 (22%)
MSD 63 (81%) 114 (56%) 64 (45%) < 0.001
UD 15 (19%) 90 (44%) 77 (54%)
No F to M 61 (78%) 163 (82%) 106 (76%) 0.429
F to M 17 (22%) 37 (18%) 34 (24%)
Missing 0 4 1
KPS < 80 8 (11%) 13 (7%) 6 (4%) 0.189
KPS ≥ 80 64 (89%) 175 (93%) 130 (96%)
Missing 6 16 5
Pat. CMV negative 17 (23%) 68 (34%) 44 (32%) 0.218
Pat. CMV positive 57 (77%) 133 (66%) 92 (68%)
Missing 4 3 5
Donor CMV negative 19 (27%) 96 (48%) 55 (41%) 0.008
Donor CMV positive 51 (73%) 103 (52%) 80 (59%)
Missing 8 5 6
MAC 32 (44%) 96 (49%) 102 (74%) < 0.001
RIC 41 (56%) 102 (51%) 36 (26%)
Missing 5 6 3
BM 58 (74%) 25 (12%) 25 (18%) < 0.001
PB 20 (26%) 179 (88%) 116 (82%)
No in vivo TCD 78 (100%) 130 (64%) 72 (51%) < 0.001
In vivo TCD 0 (0%) 74 (36%) 69 (49%)
FU follow-up, CI confidence interval, IQR interquartile range, MAC myeloablative, RIC reduced intensity conditioning regimen, PTCy post-transplant cyclophosphamide,
AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, Tx transplant, UD unrelated donor, MSD matched sibling donor, CR complete remission, PB peripheral
blood, BM bone marrow, TCD T cell depletion, CMV cytomegalovirus, KPS Karnofsky performance status
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Table 2 Multivariate analysis
HR 95% CI p value
OS
PTCy alone Reference
PT-Cy + 1 drug 0.72 0.40–1.30 0.27
PT-Cy + 2 drugs 0.49 0.26–0.93 0.03
Age (per 10 years) 1.11 0.97–1.28 0.18
AML vs. ALL 0.60 0.39–0.91 0.02
Year of Tx 0.99 0.88–1.12 0.90
UD vs. MSD 0.95 0.66–1.36 0.77
Disease status
CR1 Reference
CR2/C3 1.7 1.07–2.70 0.02
Active disease 2.48 1.71–3.59 < 0.001
RIC vs. MAC 1.20 0.83–1.74 0.34
PB vs. BM 1.13 0.69–1.83 0.63
In vivo TCD 1.07 0.72–1.60 0.73
Patient positive CMV serology 1.07 0.73–1.58 0.73
Donor positive CMV serology 1.17 0.81–1.71 0.40
Center (frailty) 0.25
GRFS
PTCy alone Reference
PT-Cy + 1 drug 0.72 0.45–1.16 0.18
PT-Cy + 2 drugs 0.51 0.31–0.84 0.007
Age (per 10 years) 0.96 0.87–1.07 0.48
AML vs. ALL 0.89 0.62–1.26 0.50
Year of Tx 0.97 0.88–1.08 0.60
UD vs. MSD 1.04 0.78–1.40 0.77
Disease status
CR1 Reference
CR2/C3 1.27 0.85–1.89 0.24
Active disease 2.18 1.61–2.95 < 0.001
RIC vs. MAC 1.32 0.98–1.77 0.07
PB vs. BM 1.30 0.87–1.94 0.20
In vivo TCD 0.83 0.60–1.16 0.27
Patient positive CMV serology 0.95 0.69–1.31 0.77
Donor positive CMV serology 1.20 0.88–1.63 0.26
Center (frailty) 0.91
LFS
PTCy alone Reference
PT-Cy + 1 drug 0.97 0.57–1.63 0.90
PT-Cy + 2 drugs 0.65 0.37–1.12 0.12
Age (per 10 years) 1.09 0.97–1.23 0.17
AML vs. ALL 0.68 0.46–0.99 0.04
Year of Tx 1 0.89–1.11 0.94
UD vs. MSD 0.92 0.659–1.27 0.60
Table 2 Multivariate analysis (Continued)
HR 95% CI p value
Disease status
CR1 Reference
CR2/C3 1.64 1.07–2.51 0.02
Active disease 2.49 1.78–3.47 < 0.001
RIC vs. MAC 1.255 0.9–1.75 0.18
PB vs. BM 0.94 0.61–1.45 0.78
In vivo TCD 1.07 0.75–1.54 0.70
Patient positive CMV serology 0.98 0.69–1.39 0.93
Donor positive CMV serology 1.24 0.89–1.74 0.21
Center (frailty) 0.91
Acute GvHD II-IV
PTCy alone Reference
PT-Cy + 1 drug 0.62 0.29–1.36 0.23
PT-Cy + 2 drugs 1.40 0.65–3.01 0.38
Age (per 10 years) 1.01 0.87–1.18 0.90
AML vs. ALL 0.53 0.33–0.85 0.008
Year of Tx 0.91 0.80–1.04 0.16
UD vs. MSD 1.66 1.06–2.60 0.03
Disease status
CR1 Reference
CR2/C3 0.62 0.32–1.19 0.15
Active disease 1.14 0.71–1.84 0.59
RIC vs. MAC 1.72 1.10–2.70 0.02
PB vs. BM 1.59 0.83–3.02 0.16
In vivo TCD 1.18 0.74–1.89 0.48
Patient positive CMV serology 0.74 0.47–1.15 0.18
Donor positive CMV serology 1.78 1.13–2.79 0.01
Center (frailty) 0.23
Chronic GvHD
PTCy alone Reference
PT-Cy + 1 drug 0.60 0.27–1.37 0.23
PT-Cy + 2 drugs 0.52 0.22–1.23 0.14
Age (per 10 years) 0.90 0.76–1.05 0.18
AML vs. ALL 1.01 0.58–1.75 0.97
Year of Tx 0.97 0.82–1.14 0.69
UD vs. MSD 0.99 0.64–1.54 0.96
Disease status
CR1 Reference
CR2/C3 0.52 0.24–1.09 0.08
Active disease 0.84 0.47–1.48 0.54
RIC vs. MAC 1.01 0.63–1.62 0.96
PB vs. BM 2.41 1.19–4.89 0.01
In vivo TCD 0.59 0.37–0.96 0.03
Patient positive CMV serology 0.88 0.55–1.43 0.61
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OS was 53% for patients transplanted from a MSD
and 77% for those transplanted from a UD (p = 0.56),
and it was 57 and 49% (p = 0.40) for AML vs. ALL,
respectively.
In multivariate analysis (Table 2), factors associated with
superior OS were the use of PT-Cy in combination with
two IS (group 1 vs. group 3; HR 0.49, 95%CI 0.26–0.93,
p = 0.02), diagnosis of AML (HR 0.59, 95%CI 0.39–0.90,
p = 0.001), and disease status at transplant (CR1 vs. CR2
HR 0.58, 95%CI 0.37–0.93, p = 0.0; CR1 vs. advanced HR
0.40, 95%CI 0.27–0.58 p < 0.001). Of note, the intensity of
the GVHD prophylaxis had an impact on GRFS (group 1
vs. group 3; HR 0.51, 95%CI 0.31–0.83 p < 0.001)
(Table 2).
Discussion
In this study, we compared the efficacy of PT-Cy GVHD
prophylaxis given alone or in combination with one or
two other immunosuppressive drugs in a homogenous
group of adult patients with acute leukemia undergoing
HSCT from MSD or 10/10 UD. We observed significant
differences in the incidence of severe cGVHD and mor-
tality in correlation with the intensity of the GVHD
prophylaxis with the combination of PT-Cy plus two IS
drugs (either CSA-MTX or CSA MMF), resulting in
improved survival.
The biological mechanism by which PT-Cy aids in
preventing GVHD after BM graft has been previously
described and involves in vivo selective destruction of
alloreactive T cells, induction of tolerance, and
intra-thymic clonal deletion of alloreactive T lympho-
cytes [17].
Table 2 Multivariate analysis (Continued)
HR 95% CI p value
Donor positive CMV serology 0.86 0.53–1.39 0.53
Center (frailty) 0.93
Extensive chronic GvHD
PTCy alone Reference
PT-Cy + 1 drug 0.57 0.21–1.56 0.27
PT-Cy + 2 drugs 0.25 0.08–0.84 0.02
Age (per 10 years) 0.76 0.63–0.96 0.02
AML vs. ALL 1.64 0.65–4.16 0.30
Year of Tx 1 0.79–1.26 0.98
UD vs. MSD 1.26 0.68–2.33 0.47
Disease status
CR1 Reference
CR2/C3 0.56 0.19–1.63 0.29
Active disease 1.24 0.57–2.68 0.59
RIC vs. MAC 1.43 0.72–2.84 0.30
PB vs. BM 4.57 1.61–12.99 0.004
In vivo TCD 0.23 0.01–0.54 < 0.001
Patient positive CMV serology 0.92 0.46–1.80 0.80
Donor positive CMV serology 0.76 0.38–1.55 0.45
Center (frailty) 0.94
Relapse
PTCy alone Reference
PT-Cy + 1 drug 1.12 0.59–2.13 0.73
PT-Cy + 2 drugs 0.82 0.42–1.61 0.57
Age (per 10 years) 1.03 0.89–1.19 0.69
AML vs. ALL 0.97 0.59–1.6 0.91
Year of Tx 1.03 0.90–1.18 0.64
UD vs. MSD 0.87 0.58–1.30 0.50
Disease status
CR1 Reference
CR2/C3 1.64 0.97–2.80 0.07
Active disease 2.42 1.60–3.66 < 0.001
RIC vs. MAC 1.18 0.78–1.77 0.44
PB vs. BM 0.83 0.50–1.38 0.47
In vivo TCD 0.89 0.57–1.39 0.61
Patient positive CMV serology 0.71 0.46–1.08 0.11
Donor positive CMV serology 1.34 0.88–2.04 0.17
Center (frailty) 0.92
NRM
PTCy alone Reference
PT-Cy + 1 drug 0.69 0.27–1.73 0.42
PT-Cy + 2 drugs 0.358 0.13–0.99 0.05
Age (per 10 years) 1.195 0.96–1.48 0.11
AML vs. ALL 0.353 0.19–0.67 0.001
Table 2 Multivariate analysis (Continued)
HR 95% CI p value
Year of Tx 0.95 0.78–1.15 0.60
UD vs. MSD 1.022 0.58–1.81 0.94
Disease status
CR1 Reference
CR2/C3 1.63 0.78–3.38 0.19
Active disease 2.949 1.65–5.27 < 0.001
RIC vs. MAC 1.339 0.74–2.42 0.33
PB vs. BM 1.247 0.56–2.78 0.59
In vivo TCD 1.47 0.78–2.75 0.23
Patient positive CMV serology 2.042 1.03–4.04 0.04
Donor positive CMV serology 1.038 0.58–1.87 0.90
Center (frailty) 0.29
HR hazard ratio, CI confidence interval, aGVHD acute graft-versus-host disease,
cGVHD chronic GVHD, NRM non-relapse mortality, OS overall survival, LFS
leukemia-free survival, GRFS GvHD-free relapse-free survival, MAC myeloablative,
RIC reduced intensity conditioning regimen, PTCy post-transplant cyclophosphamide,
AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, Tx transplant, UD
unrelated donor, MSDmatched sibling donor, CR complete remission, PB peripheral
blood, BM bone marrow, TCD T cell depletion, CMV cytomegalovirus
Ruggeri et al. Journal of Hematology & Oncology  (2018) 11:40 Page 6 of 10
The use of PT-Cy alone, without the use of any add-
itional IS drugs, for GVHD prophylaxis in the setting of
matched sibling donor or 10/10 HLA matched unrelated
donor was initially reported by Luznik [8] and, subse-
quently, in a multicenter study, [18] both demonstrating
the efficacy of this strategy. Importantly, in these studies,
BM was the sole stem cell source. Notably, these find-
ings have not been demonstrated with PBSC [19, 20].
Alousi [19] recently published the results of a phase II
clinical trial using PBSC and RIC regimen indicating an
excess of acute and chronic GVHD and NRM and there-
fore recommending the use of the standard GVHD
Fig. 1 a cGVHD, b extensive cGVHD, and c GRFS by GVHD prophylaxis strategy
Fig. 2 a RI, b NRM, c LFS, and d OS by GVHD prophylaxis strategy
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prophylaxis in HSCT following RIC regimen in combin-
ation with PBSC grafts. The same findings determined
the early closure of a different prospective phase 2 trial
after four cases of severe acute GVHD, and related tox-
icity was reported on the first five patients enrolled [20].
Similarly, an increased risk of GVHD has been re-
ported in haploidentical HSCT with PT-Cy with PBSC
grafts [21]. One may argue that the higher number of
CD3+ cells in the PBSC grafts could be in part respon-
sible for these results. Importantly, in our study, the use
of PBSC as stem cell source was significantly associated
with the increased risk of cGVHD in the multivariate
analysis, and the effect of the intensity of the GVHD
prophylaxis remained independently associated to the
risk of severe cGVHD, mortality, and survival.
In view of the high incidence of GVHD with PT-Cy as
single agent, especially in PBSC recipients, it seems that
PT-Cy should be combined with additional IS. Neverthe-
less, there is still not enough data to determine the most
effective IS drug to be used in association with PT-Cy.
In an attempt to reduce the risk of severe GVHD,
some authors [11] added CSA starting on day + 5 after
PT-Cy infusion in 43 patients with hematological dis-
eases receiving PBSC from MSD or UD. Although a
lower cumulative incidence of cGVHD and no grade
III–IV aGVHD were reported, the high incidence of
grade II aGVHD over 70% highlights the importance of
optimization of the PT-Cy GVHD prevention regimen,
in order to reduce GVHD incidence and the potential
related toxicity and mortality.
In HLA identical related and unrelated grafts, the
addition of MMF and tacrolimus to PT-Cy allowed satis-
factory control of acute GVHD (ranging 17%, with no
grade IV) resulting in very low NRM (3% at 2 years) in a
previous study [22]. Currently, a clinical trial evaluating
this GVHD prevention combination is ongoing in allogen-
eic stem cell transplantation recipients, following a MAC
or RIC preparative regimen (NCT03128359). In our study,
we are not able to evaluate this GVHD prophylaxis due to
the unbalanced distribution of this specific drug combin-
ation in our cohort (exclusively used in UD recipients and
mainly in a single center). The question of the optimal
combination remains a matter of debate not just in HSCT
from HLA matched siblings and unrelated donors but,
also, in the haploidentical setting at least until prospective
comparison study results are not available.
We are aware that in our study there may be unmeas-
ured factors that have not been considered, and this is a
limitation when conducting retrospective studies. The im-
pact of ATG could not be studied thoroughly because of
the absence of ATG in the patients receiving PT-Cy as the
sole anti-GVHD prophylaxis. We cannot discard the pos-
sibility that this could have played a role in the observed
increased incidence of graft failure and extensive cGVHD.
The protective effect of ATG in reducing cGVHD and im-
proving GRFS has been recently demonstrated in a large
phase clinical III trial [23] on transplantation of peripheral
blood stem cells from HLA identical siblings and the mye-
loablative conditioning regimen. It is possible that the
addition of ATG to PT-Cy may reduce GVHD incidence.
However, the best timing and dose of ATG in combination
with PT-Cy should be further evaluated in clinical trials.
One of the limitations of our registry-based study, includ-
ing patients in all disease status, is that some disease charac-
teristics could be confounding factors. In order to overcome
this limitation, we performed a subgroup analysis in a
homogenous group of patients with AML in CR1 and not
receiving ATG. Despite the low number of patients, the
results are consistent with those in the entire population,
but the low numbers in each subgroup prevent to achieve
enough statistical power. In our study for patients who re-
ceived PT-Cy in combination with two other IS drugs, the
benefit of adding immunosuppressive drugs to PT-Cy was
observed regardless of the use of ATG (data not shown).
The idea of sparing long-term immunosuppression by
using PT-Cy in patients with high-risk leukemia [24]
and thus reducing relapse rates, especially in the early
post-transplant period, is attractive and deserves further
investigation. Importantly, in our study, the intensity of
the GVHD prophylaxis did not modify the risk of re-
lapse. This led to an advantage in OS and, importantly,
in GRFS, which reflects the quality of life without long-
term complications related to the GVHD.
In our cohort, disease status at HSCT remained the
only factor associated with increased relapse, highlight-
ing the importance of reducing the disease burden be-
fore HSCT. In this context, some authors [25] showed
how Cy in the early post-transplant period is responsible
for a selective depletion of alloreactive T cells while spar-
ing those mediating the graft vs. leukemia (GVL). Also
recently, another group [26] reported the complete abro-
gation of the proliferation of donor-derived natural killer
(NK) cells 8 days following PT-Cy infusion in haplo-
recipients, with donor NK cells expressing less mature
phenotype NKG2A and CD26L and with slow reconsti-
tution of recipient NK cells thereafter. The mechanism
of NK cell reconstitution in the setting of MSD and UD
with PT-Cy needs to be further evaluated.
Given our results, the use of additional immunosup-
pressive drugs along with PT-Cy in matched sibling or
unrelated donor transplants is effective, reducing the risk
of graft failure and severe chronic GVHD and improving
overall survival. This strategy of GVHD prophylaxis
could be an important tool for the post-transplant
immunomodulation, also in the setting of mismatched
unrelated donor transplants, and could represent a plat-
form for early withdrawal of the immunosuppression en-
hancing the GVL in high-risk leukemic patients.
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